Global Hypertrophic Cardiomyopathy Therapeutics Market 2017-2021 - Product Image

Global Hypertrophic Cardiomyopathy Therapeutics Market 2017-2021

  • ID: 4199060
  • Report
  • Region: Global
  • 70 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • AstraZeneca
  • Gilead Sciences
  • Merck
  • Novartis
  • Pfizer
  • Sanofi
  • MORE
HCM is the enlargement of the heart muscle (myocardium), which disrupts the functions of the heart. HCM is mostly caused due to gene mutation and is a significant cause of sudden cardiac death in any age group. Hypertrophy is defined as an enlargement of a tissue or organ, and cardiomyopathy refers to diseases related to heart muscles. Therefore, HCM is defined as a condition, which is characterized by abnormal thickening of heart muscles, which makes pumping of blood from the heart to various organs difficult. Therefore, the heart must induce more pressure to pump blood to various vital organs.

The analysts forecast the global hypertrophic cardiomyopathy therapeutics market to grow at a CAGR of 1.80% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global hypertrophic cardiomyopathy therapeutics market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:

- Americas
- APAC
- EMEA

The report, Global Hypertrophic Cardiomyopathy Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- AstraZeneca
- Merck
- Pfizer
- Sanofi

Other prominent vendors
- Gilead Sciences
- Novartis
- Teva Pharmaceutical Industries

Market drivers
- Adoption of sedentary lifestyle.
- For a full, detailed list, view the full report

Market challenges
- Technological advances in devices.
- For a full, detailed list, view the full report

Market trends
- Development of translational bioinformatics (TBI).
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2021 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AstraZeneca
  • Gilead Sciences
  • Merck
  • Novartis
  • Pfizer
  • Sanofi
  • MORE
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
  • Key market highlights
PART 05: Disease overview
  • Disease overview
PART 06: Key clinical trials

PART 07: Market dynamics

PART 08: Market landscape
  • Market overview
  • Five forces analysis
PART 09: Market segmentation by drug-class
  • Global calcium channel blockers market
  • Global beta-adrenergic blockers market
  • Global antiarrhythmic market
  • Global anticoagulants market
PART 10: Geographical segmentation
  • HCM therapeutics market in Americas
  • HCM therapeutics market in EMEA
  • HCM therapeutics market in APAC
PART 11: Decision framework

PART 12: Drivers and challenges
  • Market drivers
  • Market challenges
  • Impact of drivers and challenges on key customer segments (hospitals and pharmacies)
PART 13: Market trends
  • Increasing availability of genetic tests
  • Development of TBI
  • Advent of genomic medicine
PART 14: Vendor landscape
  • Competitive landscape
PART 15: Key vendor analysis
  • AstraZeneca
  • Merck
  • Pfizer
  • Sanofi
  • Other prominent vendors
PART 16: Appendix
  • List of abbreviations
List of Exhibits

Exhibit 01: Types of HCM
Exhibit 02: Treatment for HCM
Exhibit 03: Snapshot of HCM therapeutics pipeline 2016
Exhibit 04: Pipeline analysis for HCM therapeutics market
Exhibit 05: Mutation
Exhibit 06: Identification of pathogenicity in genes by genetic testing
Exhibit 07: Global HCM therapeutics market snapshot
Exhibit 08: Global HCM therapeutics market 2016-2021 ($ millions)
Exhibit 09: Opportunity analysis in global HCM therapeutics market
Exhibit 10: Five forces analysis
Exhibit 11: Market segmentation based on drug class
Exhibit 12: Global calcium channel blockers market 2016-2021 ($ millions)
Exhibit 13: Global beta-adrenergic blockers market 2016-2021 ($ millions)
Exhibit 14: Global antiarrhythmic market 2016-2021 ($ millions)
Exhibit 15: Global anticoagulants market 2016-2021 ($ millions)
Exhibit 16: Global HCM therapeutics market by geography 2016 and 2021
Exhibit 17: Global HCM therapeutics market by geography 2016-2021 ($ millions)
Exhibit 18: Market scenario in Americas
Exhibit 19: HCM therapeutics market in Americas 2016-2021 ($ millions)
Exhibit 20: Market scenario in EMEA
Exhibit 21: HCM therapeutics market in EMEA 2016-2021 ($ millions)
Exhibit 22: Market scenario in APAC
Exhibit 23: HCM therapeutics market in APAC 2016-2021 ($ millions)
Exhibit 24: Prevalence of obesity among US adults 2015
Exhibit 25: Impact of drivers and challenges
Exhibit 26: Group of HCM individuals based on genetic tests
Exhibit 27: Competitive structure analysis of global HCM therapeutics market 2016
Exhibit 28: AstraZeneca: Key highlights
Exhibit 29: AstraZeneca: Strength assessment
Exhibit 30: AstraZeneca: Strategy assessment
Exhibit 31: AstraZeneca: Opportunity assessment
Exhibit 32: Merck: Key highlights
Exhibit 33: Merck: Strength assessment
Exhibit 34: Merck: Strategy assessment
Exhibit 35: Merck: Opportunity assessment
Exhibit 36: Pfizer: Key highlights
Exhibit 37: Pfizer: Strength assessment
Exhibit 38: Pfizer: Strategy assessment
Exhibit 39: Pfizer: Opportunity assessment
Exhibit 40: Sanofi: Key highlights
Exhibit 41: Sanofi: Strength assessment
Exhibit 42: Sanofi: Strategy assessment
Exhibit 43: Sanofi: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • AstraZeneca
  • Gilead Sciences
  • Merck
  • Novartis
  • Pfizer
  • Sanofi
  • MORE
New Report Released: - Global Hypertrophic Cardiomyopathy Therapeutics Market 2017-2021

The author of the report recognizes the following companies as the key players in the global hypertrophic cardiomyopathy therapeutics market: AstraZeneca, Merck, Pfizer, and Sanofi

Other Prominent Vendors in the market are: Gilead Sciences, Novartis, and Teva Pharmaceutical Industries.

Commenting on the report, an analyst from the research team said: “One trend in market is development of TBI. HCM is a complex genetic disorder, which requires an integration of various heterogeneous features originating from genotypic, phenotypic, and environmental sources. Modern approaches that can integrate and analyze these heterogeneous features are being developed in order to enhance the clinical guidelines for treatment and prevention of HCM and are named as TBI.

TBI is a computational approach, which focuses on the integration and analysis of bioinformatics, biostatics, statistical genetics, and clinical informatics. It acts as a data-storage source, which not only performs data integration but also improves data representation. This will be done by using tools such as ontology and controlled vocabulary, as they provide a standard way for representation of data. These vocabulary sources are references that are accepted by specific user community like Gene Ontology and the Systematized Nomenclature of Medicine-Clinical Terms (SNOMED-CT).”

According to the report, one driver in market is increasing cases of HF. HCM is an extended form of a diastolic HF when the heart fails to perform its functions normally. The diastolic HF occurs when the lower left chamber or the LV is not filled properly with blood during the diastolic phase. Therefore, the amount of pumped blood is less than the normal. Similarly, in HCM, the increasing myocardium size results in smaller LV cavity size accompanied by impairment of blood flow. This leads to the common symptoms of both HCM and HF such as dyspnoea, angina, palpitations, syncope, and presyncope. Hence, the drug development for relieving the symptoms of HF benefits the global HCM therapeutics market as well.

As per the CDC, more than five million people are living with HF in the US, and about half of the affected population succumb within five years of diagnosis. However, the deaths due to HF have significantly declined in the past few years due to improved therapies to treat the disease. However, the risk of developing HF continues to rise with the increasing population. This risk-factor has further triggered R&D for newer drugs, which can be repurposed for the diagnosis and treatment of HCM. The traditional HCM drug market has a long history of repurposed drugs for its prevention and cure. There are many drugs belonging to drug classes such as beta-adrenergic blockers, calcium channel blockers, and antiarrhythmic, which were originally developed for the treatment and prevention of HF and are now being employed in the treatment of HCM.

Further, the report states that one challenge in market is expensive serial screenings. Individuals with HCM may be asymptomatic or may complain of mild chest pain; CHF symptoms; or syncope, which is the temporary loss of consciousness due to fall in BP. The morphologic diagnosis is characterized by the presence of hypertrophied myocardium and non-dilated LV in the absence of other cardiac diseases that are capable of causing myocardium hypertrophy of more than 15 mm in an adult patient or equivalent to relative body surface area in children. The serial screening for evaluation of HCM includes two-dimensional echocardiography ($1,500), 24-hour ambulatory (Holter) electrocardiographic monitoring, 12-lead ECG, CMR, and TTE ($2,000) and evaluation by a cardiologist at an experienced center. These tests are not only time consuming but also very expensive and may pose a financial burden on an individual's family, thereby increasing anxiety and stress for the family.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • AstraZeneca
  • Merck
  • Pfizer
  • Sanofi
  • Gilead Sciences
  • Novartis
  • Teva Pharmaceutical Industries
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll